Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

844.27 -26.09 (-3.00%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
Via The Motley Fool
MarketBeat Week in Review – 02/10 - 02/14
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in 
Via MarketBeat
Topics Credit Cards Economy Government
Exposures Interest Rates Political Tariff
Top Stock Reports For Apple, Eli Lilly & Shopify
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co., and Shopify Inc., as well as a micro-cap stock ImmuCell Corp. 
Via Talk Markets
Topics Stocks / Equities
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster. 
Via MarketBeat
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Via The Motley Fool
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs. 
Via MarketBeat
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
Looking Into Eli Lilly's Recent Short Interest
Via Benzinga
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases. 
Via Benzinga
5 ETFs That Beat Market Turmoil With Gains Last Week
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs. 
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system. 
Via Stocktwits
Market Monitor February 6th
Market Recap: Wall Street Gains, Amazon Slips, and U.S. Job Growth Slows 
Via Chartmill
A Closer Look at Eli Lilly's Options Market Dynamics
Via Benzinga
Why Eli Lilly Stock Popped on Thursday
Via The Motley Fool
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
How To Ride The Market’s “Great Risk Rollercoaster”
This market is trading in an extremely tight range and has been for a long time now. It’s a market desperate for a catalyst just isn’t finding any - not in data, not in news, not in Tweets. 
Via Talk Markets
Topics ETFs Stocks / Equities
Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets
Wall Street cautious on mixed earnings, macroeconomic data, and geopolitical developments. Gold hits record high while Ford's outlook disappoints.Wall St cautious due to mixed earnings, data &... 
Via Benzinga
Topics Economy
Exposures Interest Rates
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Shares rocketed on Friday, but the company might not be out of hot water yet. 
Via Investor's Business Daily
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). 
Via Benzinga
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
LLY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Trump Focused On 10-Year Yield And Not On The Fed, Slower AI Growth Fears Weigh On Arm Stock
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Interest Rates Political
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.